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Cohort studies have demonstrated that the strong 
association between (blood pressure (BP) and stroke 
appears to be continuous down to levels of at least 
115/75 mm Hg. Th e strength of the associations was 
similar for men and women and  for fatal and nonfatal 
events but attenuated with age. Despite a potentially 
weaker relative association for older age groups, the 
higher overall stroke rate in this group means that in 
absolute terms, the benefi ts of a given reduction in BP 
are likely to be greater. Th e analyses have not consis-
tently demonstrated a diff erence in the association be-
tween intracerebral hemorrhage and ischemic stroke. 
Regional comparisons are  very limited because most 
of the cohort studies have been conducted primarily in 
the “developed” parts of the world. Th e broad consis-
tency of the results across overviews was more evident 
than any diff erences. Th e proportional associations 
are likely to be reasonably generalizable to the many 
populations in the world for which there are limited 
data on stroke epidemiology.
Data from trials provide more reliable data on the 
likely short-term benefi ts of BP lowering on stroke. 
Randomized controlled trials have been conducted 
predominantly in populations of Western countries, 
and data for developing countries (where approximate-
ly three quarters of stroke deaths occur worldwide) are 
very scarce. Th e results of the updated meta-analysis 
of trials are consistent with those of several previ-
ous meta-analyses and confi rmed the risk reduction 
of stroke with BP lowering compared with placebo 
(regardless of the agent used) as being between 30% 
and 40%. Limited data were available on treatment 
eff ects by age, and the treatment eff ects by age with-
in individual trials and between trials  have not been 
consistent. Few data are available on stroke subtypes, 
limiting the scope for meta-analyses. Th e limited data 
from the Perindopril Protection Against Recurrent 
Stroke Study  and the Heart Outcomes Prevention 
Evaluation  study are insuffi  cient to draw defi nitive 
conclusions regarding the impact of BP lowering on 
stroke subtypes. Analyses have indicated that a more 
intensive BP-lowering regimen with a given agent 
may produce a greater risk reduction  than a less in-
tensive regimen and that overall the trials demonstrate 
a dose-response relationship between magnitude of 
BP reduction and reduction in risk of stroke. When 
diff erent classes of BP-lowering drugs were directly 
compared, there was very little diff erence in either the 
magnitude of the BP reduction achieved or the impact 
of diff erent agents on stroke. Th e similarities between 
the eff ects of diff erent drug classes are more striking 
than the diff erences, but there is uncertainty over the 
extent to which any diff erences are explained by dif-
ferences in BP reduction and chance.
